Akums Drugs and Pharmaceuticals Limited — Investor Meet, 17-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Akums' Q2 FY26 revenue was INR 1,018 crore (-1.5% YoY), with EBITDA at INR 94 crore (-22% YoY) and margins at 9.3%. This dip was attributed to broad-based API price declines (8% impact) and costs from ramping up new facilities, despite CDMO volume growth of 7% and improved gross margins. Key developments include a Zambia JV (51% stake, US$45M project, 2028 production), with US$50M supply from India by 2027. European CDMO contract progresses; first commercial supply dispatched. Management is focused on API turnaround and domestic growth. Cash surplus is INR 1,649 crore. The outlook is confident on long-term growth via strategic partnerships and efficiency, with an eye on M&A.